Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MPO | P05164 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7434865 | 1.00 | ALDH1A1 (0.58) | ALDH1A1MAPTRECQLGAAKMT2A | |
| SCHEMBL16099676 | 1.00 | ALDH1A1 (0.58) | ALDH1A1MAPTRECQLGAAKMT2A | |
| SCHEMBL16099677 | 1.00 | ALDH1A1 (0.58) | ALDH1A1MAPTRECQLGAAKMT2A | |
| SCHEMBL30343690 | 1.00 | ALDH1A1 (0.58) | ALDH1A1MAPTRECQLGAAKMT2A | |
| SCHEMBL19456372 | 0.84 | ALDH1A1 (0.41) | ALDH1A1MAPTRECQLGAAKMT2A | |
| SCHEMBL30711166 | 0.84 | PLA2G2A (0.48) | ALDH1A1MAPTRECQLSCN9ASLC7A5 | |
| SCHEMBL19410203 | 0.84 | PLA2G2A (0.48) | ALDH1A1MAPTRECQLSCN9ASLC7A5 | |
| SCHEMBL19410201 | 0.84 | PLA2G2A (0.48) | ALDH1A1MAPTRECQLSCN9ASLC7A5 | |
| SCHEMBL16100108 | 0.84 | CTSS (0.48) | GAAPOLBSCN9AHDAC10HDAC6 | |
| SCHEMBL31407630 | 0.84 | CTSS (0.48) | GAAPOLBSCN9AHDAC10HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022142-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2026-01-22 | — | — | US | disclosed |
| EP-4526323-A1 | MACROCYCLIC IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2025-03-26 | — | — | EP | disclosed |
| EP-4499667-A1 | MACROCYCLIC IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2025-02-05 | — | — | EP | disclosed |
| CN-119013287-A | Macrocyclic immunomodulators | 百时美施贵宝公司 | 2024-11-22 | — | — | CN | disclosed |
| EP-4441069-A1 | MACROCYCLIC IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2024-10-09 | — | — | EP | disclosed |
| CN-118613490-A | Macrocyclic immunomodulators | 百时美施贵宝公司 | 2024-09-06 | — | — | CN | disclosed |
| EP-4419540-A1 | IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2024-08-28 | — | — | EP | disclosed |
| CN-118159549-A | Immunomodulators | 百时美施贵宝公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-118076623-A | Macrocyclic immunomodulators | 百时美施贵宝公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-117940445-A | Macrocyclic immunomodulators | 百时美施贵宝公司 | 2024-04-26 | — | — | CN | disclosed |
| WO-2024059472-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-03-21 | — | — | WO | disclosed |
| EP-4314012-A1 | IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-117157306-A | Immunomodulators | 百时美施贵宝公司 | 2023-12-01 | — | — | CN | disclosed |
| WO-2023225661-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023192873-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023102507-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023069994-A1 | IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2022204412-A1 | IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022142-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | ALDH1A1 746/4885MAPT 4702/4885RECQL 3138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.